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ABSTRACT (150/150 words) 
Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into 
routine care remains limited. Opportunely, several implementation studies and programmes have 
been initiated over recent years. This article presents an overview of these studies and identifies 
current research gaps. Importantly, one such gap is the undetermined collective clinical utility of 
implementing a panel of PGx-markers into routine care, because the evidence base is currently 
limited to specific, individual drug-gene pairs.  The Ubiquitous Pharmacogenomics Consortium (U-
PGx), which has been funded by the European Commission’s Horizon-2020 programme, aims to 
address this unmet need. In a prospective, block-randomized, controlled clinical study (PREPARE), 
pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are 
available, will be implemented across healthcare institutions in seven European countries. The 
impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its 
multi-center, multi-gene, multi-drug, multi-ethnic, and multi-healthcare system approach.  
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INTRODUCTION 
Pharmacogenomics in precision medicine 
Pharmacogenomics (PGx) informed prescribing is one of the first applications of genomics in 
medicine (1, 2). It promises to personalize medicine by using an individual’s genetic makeup, which 
predicts drug response, to guide optimal drug and dose selection (3, 4). This removes the traditional 
‘trial and error’ approach of drug prescribing, thereby promising safer, more effective and cost-
effective drug treatment (5, 6). The discrepancy between germline and somatic PGx is of importance 
with regard to PGx clinical implementation (7). Despite significant progress in the field of somatic 
precision medicine, it is outside the scope of this review. Several randomized controlled trials (RCTs) 
have provided gold-standard evidence for the clinical utility of single drug-gene PGx tests to: 1) guide 
dosing for warfarin, (8, 9), acenocoumarol, phencopromon (10), and thiopurines (11), and; 2) guide  
the drug selection of abacavir (12). Additionally, several prospective cohort studies have been 
performed indicating the clinical utility of single drug-gene PGx tests to guide drug selection of 
carbamazepine (13) and allopurinol (14). Many argue though that the perceived mandatory 
requirement for prospective evidence to support the clinical validity of a PGx test, prior to its 
implementation into routine care, is incongruous and excessive (15-18). The notion of “genetic 
exceptionalism” has been held responsible (19). Several recent studies estimate that 95% of the 
population carry at least one actionable genotype (20, 21). Since actionable PGx variants are 
ubiquitous and germline PGx results are life-long, we consider that quantifying the collective clinical 
utility of a panel of PGx-markers to be more relevant than providing evidence for individual drug-
gene pairs. This will, however, still require the systematic implementation of a pre-emptive PGx 
strategy across multiple drugs, genes and ethnicities, and the robust assessment of this 
interventions impacts on both individual patient care and healthcare service processes. It is our 
expectation that the generation of such evidence will support the population-wide implementation 
of pre-emptive PGx testing. 
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Barriers preventing PGx implementation  
There have been advances in PGx implementation, but significant barriers remain, including those 
preventing clinical implementation (22-26). The remaining hurdles include improving physician and 
pharmacist awareness and education about PGx (27, 28), the development of tools to implement 
PGx results into the workflow of physicians and pharmacists (29, 30) and the undecided 
reimbursement of PGx tests. Finally, and most importantly, evidence presenting the collective 
clinical utility of a panel of PGx-markers remains to be established. It is envisaged that surpassing 
these daunting barriers will provide the impetus for the widespread adoption of both the Dutch 
Pharmacogenomics Working Group (DPWG) guidelines (31, 32) and the Clinical Pharmacogenetics 
Implementation Consortium (CPIC) guidelines (33-46), which will help to realise the potential of PGx. 
Current implementation projects are addressing these barriers 
Several of the documented hurdles obstructing the implementation of PGx are currently being 
addressed by various initiatives, both in the United States and the European Union. A compact 
overview of these initiatives is provided in the following sections. From this overview, both trends 
and remaining research gaps have been identified. Various initiatives attempt to increase physician 
and pharmacist knowledge of PGx, and a diverse range of tools have been developed to integrate 
PGx testing results into their workflow. A significant research gap which, however, remains unmet is 
the absence of evidence presenting the collective clinical utility of a panel of PGx-markers. The 
Ubiquitous Pharmacogenomics Consortium (U-PGx), therefore, aims to provide this evidence in a 
large-scale, multi-drug, multi-gene, multi-center, multi-ethnic, approach to PGx testing. 
The Ubiquitous Pharmacogenomics Consortium (U-PGx) 
The U-PGx Consortium is an established network of European experts equipped to address the 
remaining challenges and obstacles for clinical implementation of PGx into patient care (16). Funded 
by a 15 million Euro Horizon 2020 grant from the European Commission, the U-PGx Consortium aims 
to make actionable PGx data and effective treatment optimization accessible to every European 
citizen. The U-PGx consortium will investigate the impact on adverse event incidence and healthcare 
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costs following the widespread implementation of pre-emptive PGx testing using a panel of clinically 
relevant markers. As opposed to many other implementation initiatives, U-PGx will implement PGx 
through a pre-emptive panel strategy as opposed to implementing an individual drug-gene pair. For 
reasons stated above, this approach is designed to provide relevant evidence supporting the 
implementation of PGx in routine care. U-PGx uses a multifaceted approach consisting of four 
components to achieve this objective, as shown in Figure 1, and members of each component are 
mapped in Figure 2. The first component focuses on developing the enabling tools necessary to 
integrate PGx test results into the electronic health record (EHR) and clinical decision support system 
(CDSS), taking into account the differences in health care models, languages and laws across the EU. 
These enabling tools consist of information technology (IT) solutions, PGx testing infrastructure, 
educating healthcare professionals in PGx, and translating the existing DPWG guidelines, which were 
updated only in Dutch language, to six other local languages. This component will pave the way for 
the unobstructed operation of component two. This second component will implement pre-emptive 
genotyping of a panel of 50 variants in 13 pharmacogenes into clinical practice, in the context of a 
large prospective, international, block-randomised, controlled study (n=8,100). This study is called 
the PREPARE study (PREemptive Pharmacogenomic testing for prevention of Adverse drug 
REactions). Primarily the study aims to assess the impact of PGx implementation on adverse event 
incidence. Additional outcomes include cost-effectiveness, process indicators for implementation 
and provider adoption of PGx. A third component applies innovative methodologies such as next-
generation sequencing (NGS), pharmacokinetic modelling and systems pharmacology to discover 
additional variants associated with drug response and to elucidate drug-drug-gene interactions. The 
final, fourth, component will focus on ethical issues of the project and implications for PGx, and 
spearheads outreach and educational activities to influential stakeholders. In comparison to the US, 
projects within the EU likely encounter even more challenges to achieve implementation because of 
the multi-linguistic settings, different legal environments and heterogeneous healthcare systems of 
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EU countries. The specific approaches adopted by these components and the design of the PREPARE 
study are further elaborated in the following sections. 
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OVERVIEW OF CURRENT IMPLEMENTATION STUDIES  
Several implementation studies have been initiated in the United States since 2010. An overview of 
published initiatives is given in Table 1. Additional, unpublished, initiatives may exist outside the 
scope of this table. A subsection of these studies has previously been summarized elsewhere (20).  In 
the following sections the objectives and implementation strategies of these clinical implementation 
studies and programmes are summarized.  
Cleveland Clinic’s Personalized Medication Program  
The Cleveland Clinic established the Center for Personalized Healthcare in 2011, to incorporate 
unique patient characteristics, including genetics, into the medical decision making process. The 
center has developed two programs, one of which is the Personalized Medication Program. This 
program was launched in 2012 aims to identify drug-gene pairs ready for integration into clinical 
practise and developing the tools needed to implement into the clinical workflow. The program has 
currently implemented HLA-B*1502-abacavir and TPMT-thiopurines into the clinical workflow and 
aims to implement two additional drug-gene pairs per year. An oversight committee selected these 
drug-gene pairs. Alerts and custom rules have been developed in the EHR to provide clinicians with 
point-of-care PGx decision support. A clinical pharmacogenomics specialist provides support for both 
patients and clinicians who require help with understanding the PGx results. Future goals also 
include development of an algorithm which identifies patients who are at high-risk of receiving a 
drug for which pre-emptive genotyping would be useful .  
CLIPMERGE PGx 
As part of the eMERGE-PGx project, Icahn School of Medicine at Mount Sinai has initiated the 
CLIPMERGE PGx Project for implementing PGx testing into the EHR and CDSS by using a biobank 
derived cohort, from the BioMe Biobank. Patients enrolled in the biobank, who are likely to receive a 
drug with genetic interactions and receive primary care at Mount Sinai Internal Medicine Associates, 
are eligible for inclusion. 1,500 pilot patients are being pre-emptively genotyped for known variants 
associated with drug response. CLIPMERGE-PGx aims to provide valuable insight into the 
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mechanisms, tools and processes that will best support the use of PGx in clinical care. The 
investigators argue that before personalized medicine can be realized, tools and best practices to 
facilitate the delivery of PGx must be developed and evaluated so that the question of utility can be 
answered without the burden of a questionable process (48). As an initial result, a study among 
included physicians suggested they have a deficit in their familiarity and comfort in interpreting and 
using PGx (49). 
Electronic Medical Records and Genomics Network-Pharmacogenomics (eMERGE-PGx) 
The eMERGE-PGx is a partnership of the Electronic Medical Records and Genomics Network 
(eMERGE) (50) and the Pharmacogenomics Research Network (PGRN) (51, 52). eMERGE-PGx is a 
multi-center project which aims to implement targeted sequencing of 84 pharmacogenes and assess 
process and clinical outcomes of this implementation at ten academic medical centers across the 
United States. The goals of eMERGE-PGx are threefold: 1) to install a NGS sequencing platform to 
assess sequence variation in 9,000 patients likely to be prescribed a drug of interest in a one- to 
three-year timeframe across the ten clinical sites; 2) to integrate clinically validated genotypes into 
the EHR and CDSS and to measure the resulting clinical outcomes and assess the implementation 
process, and; 3) to develop a repository of variants of unknown significance linked to clinical 
phenotype data to expand PGx understanding (53).  
Implementing Genomics in Practice (IGNITE)  
IGNITE is a network of six sites and a coordinating center which aims to develop methods for, and 
evaluate the feasibility of, incorporating and individual patient’s genomic information into their 
clinical care. The network was established in 2013 and supports the development and investigation 
of genomic practice models which are integrated into electronic medical records to inform decision 
making at the point of care. Three of these sites focus on implementing PGx testing in clinical care: 
Indiana University (INGENIOUS), University of Florida (Personalized Medicine Program), Vanderbilt 
University (I3P) (54). 
INdiana GENomics Implementation: an Opportunity for the Under Served (INGENIOUS)  
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Indiana University School of Medicine and the Indiana University Institute of Personalized Medicine, 
in collaboration with the Eskenazi Health System, are conducting an NIH funded trial, which started 
recruitment in March 2015. INGENOUS implements pre-emptive PGx genotyping of a panel of 
pharmacogenes through a randomized clinical trial. INGENIOUS is prospectively enrolling a total of 
6,000 patients, with 2,000 patients assigned to the PGx testing arm and 4,000 to the control arm. 
Both arms will be followed for a year after being prescribed a targeted medication. Open Array 
genotyping will assess 43 variants in 14 genes known to affect the response of 28 drugs. Primary 
outcomes include adverse event incidence and annual healthcare cost. PGx results are integrated in 
the EHR and CDSS. Additionally, participating physicians are supported with provided consultations 
in using the PGx results in routine care (55, 56).  
Personalized Medicine Program  
The University of Florida and Shands Hospital launched the Personalized Medicine Program in 2011 
to ensure the clinical implementation of PGx-based prescribing. The pilot implementation project 
focussed on implementation of clopidogrel-CYP2C19 drug-gene pair and future plans include 
expansion to additional drug-gene pairs. The initiative developed a cost-effective PGx genotyping 
array (57). A specialized hospital regulatory body is responsible for regulating which clinically 
relevant PGx markers are migrated to the medical record and CDSS. As of March 2013, CYP2C19 
genotypes of 800 patients have been incorporated in their medical records (58). 
PG4KDS  
Through a research protocol St. Jude Children’s Research Hospital’s PG4KDS aims to selectively 
migrate PGx genotype tests into routine patient care so that results are available pre-emptively. 
Genotyping is performed using the DMET assay (59). The ultimate objective is to migrate all CPIC 
gene-drug pairs into the EHR, to facilitate PGx-based prescribing, and for it to ultimately become 
routine care. A PGx oversight committee evaluates whether drug-gene pairs are qualified for 
migration into the EHR. Interruptive pre-test alerts are fired when a drug linked to a drug-gene pair 
is prescribed, informing physicians that the patient does not yet have a documented genotype (29). 
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Post-test alerts are fired when the genotype is available in the patient’s EHR. Patients have the 
option to consent to individualized notification every time a new genetic test result is placed into 
their EHR. Additionally, educational efforts are focused at both patients and clinicians. As of August 
2013, 1,559 patients had been enrolled and four genes and 12 drugs have migrated to the EHR (60).  
Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program 
In 2011 the PGRN established the Translational Pharmacogenetics Program to assess 
implementation within six diverse health-care systems. The project’s aim is to assess the 
implementation of routine evidence-based pharmacogenetic testing .Each site will implement PGx 
testing of one or more drug-gene pairs, as per the CPIC guidelines, either through a clinical trial or 
through implementing into clinical practice. Implementation strategies include both through point-
of-care and pre-emptive models. Process metrics for implementation are tracked among all sites, to 
assess the effectiveness of implementation (52). 
Pharmacogenomics Resource for Enhanced Decisions in Care and Treatment (PREDICT) Project  
As part of the eMERGE-PGx project, Vanderbilt University has initiated the PREDICT Project. The aim 
is to develop the infrastructure and framework for incorporating PGx results into the EHR and 
making these available to healthcare professionals at the time of prescribing. Initially, the 
implementation focussed on CYP2C19 genotyping for patients receiving antiplatelet therapy after 
having undergone cardiovascular stent insertion. The enrolment focus is on groups of patients with 
anticipated cardiac catheterization with coronary artery stenting, but providers are not limited to 
enrolling patients within this therapeutic area (21). As of November 2013, 10,000 patients had been 
genotyped and several other drug-gene pairs have been implemented (61). 
Right Drug, Right Dose, Right Time (RIGHT)  
As part of the eMERGE-PGx project, Mayo Clinic has initiated the RIGHT Project. The aims the project 
is to develop best practice for integrating both PGx results and CDSS into the EHR to make PGx 
results available to prescribers pre-emptively at the point of care. As of July 2013, 1,013 Mayo Clinic 
Biobank participants were included in the study and four gene-drug pairs were approved for 
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implementation and several others were in under development for integration within the CDSS (20). 
Initially, patients were eligible for enrolment if they had a high risk of initiating statin therapy within 
three years, as this subset of patients would likely benefit from a PGx-driven intervention. These 
participants were identified through a multivariable prediction model (62). Pre-emptive PGx testing 
included targeted sequencing of 84 PGx genes and additional CYP2D6 genotyping because of 
technical difficulties with sequencing CYP2D6. As a interim result, challenges have been identified 
which require multi-disciplinary and multi-institutional efforts to make PGx guided drug and dose 
selection routine care. (63) 
The 1,200 Patients Project   
The University of Chicago has initiated the 1,200 Patients Project and aims to determine the 
feasibility and utility of incorporating pre-emptive PGx testing into clinical care. This observational 
study involves the implementation of novel genomic prescribing system (GPS) to deliver a patient-
specific interpretation of complex genomic data for a particular drug, distilled into a short summary 
(64). Outcomes of the study include, whether physicians take PGx information into consideration, 
and whether this results in altered prescribing patterns in patients at high risk for ADR or non-
response. Future aims include an examination of the impact of providing PGx results on prescribing 
decisions and patient outcomes (65). Following recruitment of 821 patients, initial results of the 
project demonstrate a high level of patient interest in PGx testing, and physician adoption and 
utilization of PGx information through the GPS (66). 
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CURRENT PGX IMPLEMENTATION STUDIES: TRENDS AND REMAINING RESEARCH GAPS  
From this overview, trends among initiatives and remaining knowledge gaps can be identified.  
Trends Across Clinical Implementation Studies 
Similarities across clinical implementation studies include: integrating the PGx test results into the 
EHR and CDSS at the point of care to guide healthcare providers in using results in patient care; 
implementation of the existing CPIC guidelines; implementing single drug-gene pairs one at a time 
and assessing their clinical utility; educating healthcare providers in PGx; and expanding the field of 
PGx by making use of NGS techniques. Individual initiatives have additionally addressed the utility of 
PGx in subpopulations such as paediatrics (60, 67) and polypharmacy (68, 69), where the impact of 
PGx may be greater.  
Remaining Knowledge Gaps 
Although many implementation studies are addressing the remaining barriers, important knowledge 
and research gaps remain. One remaining gap is demonstrating quantifiable patient and economic 
benefit from a PGx testing strategy that focuses, not on a single gene-drug pair, but rather on a 
panel of pharmacogenes across various therapeutic areas. This evidence could enable evidence-
based decision making to shape policy. Further PGx investigations are also required to deepen our 
understanding of drug response phenotype-genotype associations. This deeper understanding of 
PGx is urgently needed to increase the predictive accuracy, benefits and impact of PGx. An important 
additional area for attention is the design of implementation models that are transferable and 
feasible for institutes not as highly specialized as the early adopting sites featured in Table 1.  
The U-PGx Consortium was established to address these critical remaining research gaps in addition 
to observing the aforementioned state-of-the-art trends. The U-PGx consortium strives to provide 
evidence regarding the clinical utility of PGx testing using a panel of pharmacogenes, provide 
evidence of cost-effectiveness, and to expand the field of PGx by both NGS and systems 
pharmacology approaches. U-PGx is one of the few implementation studies assessing the combined 
clinical utility of multiple drug-gene pairs and is therefore strategy specific as opposed to drug-gene 
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pair specific. U-PGx is also the first to implement PGx across countries, and therefore across many 
ethnicities and healthcare systems. U-PGx is also not limited to implementing PGx in highly 
specialized institutions, and will therefore obtain different process metrics for implementation than 
early-adopting institutions, where providers may have more PGx know-how. U-PGx is also the first 
study implementing the DPWG guidelines as opposed to the CPIC guidelines. Similar to many 
implementation studies, U-PGx will integrate PGx results into the workflow of healthcare providers, 
aims to educate both physicians in pharmacists in PGx, and measure process metrics for 
implementation. 
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UBIQUITOUS PHARMACOGENOMICS CONSORTIUM (UPGx) 
Overcoming Implementation Barriers  
Enabling tools 
As of October 2016, a variety of enabling tools have been developed to facilitate implementation of 
PGx testing in a wide range of healthcare systems across the European Union. A detailed analysis of 
existing data management systems (both electronic and paper-based) at clinical sites has been 
conducted to guide the development of CDSS implementation strategies in U-PGx. To accommodate 
the widely varying capabilities and needs of data management systems at different implementation 
sites, a spectrum of complementary CDSS solutions were developed . Specifically, to make PGx data 
and CDSS available in health care systems where an EHR is unavailable, the “Safety-Code card” has 
been adopted (70). This card is part of a mobile-based CDSS called the Medication Safety Code (MSC) 
system that is independent of existing IT infrastructures, and enables quick retrieval of patient-
relevant PGx drug dosing guidelines (Figure 3). The MSC system does not require central patient 
data storage. Instead, the “Safety-Code card” contains a QR code that stores the patient’s encoded 
PGx results. It can be decoded and interpreted by common smartphones and other devices. After 
scanning the QR code, the medical professional is led to a website that provides drug dosing 
recommendations customized to the PGx profile of the patient. In the context of PREPARE, the MSC 
system is aimed to serve as an auxiliary tool to maximize the accessibility and sharing of PGx results 
within and between different health care settings and health care professionals. Patients will be 
asked to show their “Safety-Code card” to physicians and pharmacists who prescribe or dispense 
drugs to them during the follow-up period of the study. These physicians and pharmacists can thus 
use the patient’s PGx results to guide drug and dose selection. Concomitantly, patients will be asked 
to report prescriptions of additional newly started drugs to research nurses during the follow-up 
period.   
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Knowledge base curation and the automated translation of genetic data to associated phenotypes 
and recommendations will be handled by the Genetic Information Management Suite (GIMS) 
created by the U-PGx partner bio.logis Genetic Information Management (71). The GIMS Diagnostic 
Report Module holds the CE Mark according to according to EEC 93/42, EC 2007/47. The CE mark for 
a medical device not only certifies the product’s quality according to valid European guidelines but 
also confirms its fitness to be used for the intended medical purpose. The authorities responsible for 
monitoring the manufacturer’s compliance with the relevant European regulations are the German 
Institute of Medical Documentation and Information (DIMDI) as well as the Federal Institute for 
Drugs and Medical Devices (BfArM). In addition the Diagnostic Report Module has been certified as 
an “Internet medicine quality product” by the Federal Association for Internet Medicine (BiM). 
The Dutch Pharmacogenomics Working Group Guidelines 
In 2005, the Royal Dutch Pharmacists Association (KNMP) established the DPWG with the objective 
to develop pharmacogenetics-based therapeutic recommendations based on a systematic review of 
the literature. The DPWG consists of 14 members including clinical pharmacists, community 
pharmacists, general practitioners, physicians, clinical chemists, epidemiologists and a toxicologist. 
Currently, the database consists of 84 drug-gene combinations comprising 13 genes. DPWG 
guidelines are integrated in the “G-Standaard” (the Dutch national drug database) and are 
incorporated into all electronic systems for drug prescribing and dispensing in the Netherlands. As 
part of U-PGx, the DPWG guidelines (31, 32) have been translated into all local languages (from 
Dutch to English, German, Greek, Slovenian, Spanish and Italian) by certified professionals.  
Genotyping platform and variant selection 
The LGC Group SNPline™ platform will be deployed at all implementation sites, ensuring 
homogenous genotyping across the project. The SNPline platform is a flexible and scalable solution 
for PCR-based genotyping. It is comprising a workflow that enables the user to generate up to more 
than 1,000 ,000 data points per day. Additionally, it retains the flexibility to run individual repeats 
17 
 
without consuming arrays and producing far more data than needed. The variants included in the 
panel were selected systematically by pre-specified criteria. The criteria for variant selection are 
listed in Supplemental Table S1. The selection yielded 50 variants in 13 pharmacogenes. Variants 
included in the panel and their associated phenotypes are listed in Supplemental Table S2. 
Pharmacogenomics education 
Provider and patient education and support are crucial for successful implementation of PGx. E-
Learning programs will be prepared with the aim of developing an e-learning based knowledge 
platform for the participating countries and partners. This e-learning platform will be used to 
distribute the PGx knowledge required by physicians and pharmacists to make use of PGx in patient 
care. Using electronic education methods, lectures will cover the main themes that are regarded 
necessary for the use and implementation of PGx and will be offered to schools of medicine, schools 
of pharmacy and post-academics. These will cover the basics of PGx, drug metabolism, drug dosing, 
targeted therapies, regulation and guidelines for PGx diagnostics in drug development and 
pharmacovigilance, companion diagnostics, obligatory genetic tests, good genomic practice and PGx 
information in drug labels. The level of knowledge and opinion on PGx among physicians and 
pharmacists at the start and at the end of the project will be investigated through surveys. The aim 
is to assess the level of knowledge about PGx among healthcare professionals to identify knowledge 
gaps which may hinder the implementation of PGx testing in routine care. 
The PREPARE Study  
Overall study design 
PREPARE is an international prospective, multi-center, open, block-randomized, study. Figure 4 
illustrates the PREPARE study design. The PREPARE study [Clinicaltrials.gov Number – registration 
pending] will investigate the impact of pre-emptive genotyping of a panel of clinically relevant PGx-
markers on patient outcomes. It is unique in its multi-center, multi-gene, multi-drug, multi-ethnic, 
and multi-healthcare system approach. It is hypothesized that implementing PGx guided drug and 
dose selection will decrease clinically relevant ADRs by 30% (from 4% to 2.8%). Pre-emptive PGx 
18 
 
testing will be implemented in clinical sites across seven European countries (United Kingdom, The 
Netherlands, Austria, Greece, Slovenia, Italy and Spain). The PREPRARE protocol has been submitted 
for ethical approval, locally, in all seven countries. The study will be performed in accordance with 
the Helsinki Declaration of 1975 (as revised in 1983). The 36-month study is split into two 18-month 
blocks. The participating countries are randomized to start with either implementing PGx guided 
prescribing or with standard of care for the first block. After this 18-month block, the countries 
switch to implementing the opposite strategy and will recruit new patients (i.e. patients recruited 
into one of the arms cannot be re-recruited into the other arm). Both patients and research teams 
cannot be blinded; the PGx results will be used to guide drug and dose selection, and patients will 
receive their PGx results on a “Safety-Code card”.  In total, 8,100 patients will be recruited; 4,050 
patients in the intervention arm and 4,050 patients in the control arm. Each implementation site will 
concentrate on, but is not limited to, recruiting patients within a specific therapeutic area. 
Therapeutic areas include primary care, general medicine, cardiology, oncology, psychiatry, 
neurology, and transplantation. The PREPARE study schema is illustrated in Figure 5. 
Patient recruitment 
Adult patients who receive a first prescription for a drug listed in Table 2 (drugs for which a DPWG 
dosing recommendation is available), within routine care, will be identified and are eligible for 
inclusion. Inclusion and exclusion criteria are listed in Supplemental Table S3. This first drug that is 
included is referred to as the “index drug”. To ensure that there is a balanced patient and drug 
population among intervention and control arms, inclusion of any given index drug is limited to 10% 
in both the intervention (n=405) and control arms (n=405).  
Drug selection 
DPWG guidelines to guide dose and drug selection are available for more drugs than are included in 
the PREPARE study. Table 2 includes all drugs for which an actionable drug-gene interaction is 
present according to the DPWG recommendations with the exception of abacavir, omeprazole, 
esomeprazole, lansoprazole, pantoprazole, and rabeprazole. Abacavir is excluded because PGx-
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guided prescribing is mandatory in routine care. Proton pump inhibitors are excluded because the 
DPWG recommendations are only associated with differences in efficacy, rather than ADR 
frequency, amongst aberrant genotypes (where ultra-rapid metabolisers are recommended a higher 
dose to ensure sufficient blood levels for an efficacious pharmacotherapy). Oestrogen containing 
drugs will not serve as an index drug, but are incorporated into the study if newly started in a patient 
already recruited onto PREPARE during study follow (see below ‘subsequent drugs’).  
The PGx intervention 
A DNA sample is collected at recruitment for genotyping of a panel of 50 variants in 13 
pharmacogenes. The PGx results of patients in the study arm only will be used to guide drug and 
dose selection as per the DPWG guidelines. These results will be provided to the prescribing 
physician or dispensing pharmacist with a maximum turnover time of three-working days.  
Follow-up 
Follow-up by the research team will assess incident adverse drug events, (index) drug modifications, 
drug adherence, quality of life, costs, co-medication and attitudes towards PGx. Assessment of 
adverse drug reactions will be performed by the research team and will involve causality, severity 
and genotype correlation assessments. Incident adverse drug reactions collected by the research 
team will contribute to the primary composite endpoint (see primary composite endpoint). The 
research team will contact patients at four weeks, twelve weeks and at the end of the study arm by 
telephone (out patients) or in person (in patients). Various open questions will be posed to identify 
adverse events experienced by the patient, followed by a series of closed questions to identify 
specific adverse events associated with the drug of interest. 
In parallel, patient reported outcomes will be monitored through an established web-based platform 
developed by the Netherlands Pharmacovigilance Center Lareb, and will only be used as a secondary 
outcome. This web-based intensive monitoring system has been validated in several clinical trials as 
a feasible and accurate method for collecting adverse drug event data (72). This aspect of the study 
is important as patient reported adverse events may differ from those collected by the research 
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team (73). Reporting patients will provide assessments of severity and causality of their own adverse 
event. Patient reported severity will be measured by using a scale based on the Patient-Reported 
Outcome-Common Toxicity Criteria (PRO-CTCAE) (74).  
Subsequent prescriptions of drugs of interest 
Patients are requested to notify the research team every time they receive a prescription for one of 
the 43 drugs of interest (as listed in Table 2) during follow-up. These drugs are referred to as 
“subsequent drugs”. This will trigger an identical three-month follow-up, as for the index drug (as 
illustrated in Figure 5). Patients are requested to provide their (mock) “Safety-Code card” to 
physicians that manage them or dispensing pharmacists. Healthcare providers will have the ability to 
make use of the PGx results to guide drug and dose selection at the point of consultation; in the 
contrast to the index drug, where a thee working day lag-time is unavoidable. There is recognition 
for the fact that the research team is fully reliant on patient report of subsequent prescriptions, in 
order to trigger follow-up for this subsequent prescription. This could introduce selection bias. 
Therefore, incident adverse drug reactions resulting from subsequent prescriptions will only be used 
as a secondary outcome. 
Primary composite outcome 
All adverse events are monitored during follow-up by the research team are classified according to 
causality, severity and drug-genotype association. Causality will be classified using the Liverpool 
Causality Assessment Tool (75). Severity will be classified using the National Cancer Institute 
Common Toxicity Criteria for Adverse Events (NCI-CTCAE) scale. The drug-genotype association will 
be assessed using the DPWG guidelines (31, 32). To ensure homogenous assessment across all sites, 
the Netherlands Pharmacovigilance Center Lareb will blindly reassess a random selection of adverse 
drug events. Adverse drug events contributing to the composite primary endpoint are illustrated in 
Figure 6. All ADRs which contribute to the primary endpoint, contribute equally; regardless of their 
severity.  
Primary analysis 
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A gatekeeping analysis will be performed for the primary analysis only amongst patients who had an 
actionable drug-genotype combination for the index drug. This first analysis will compare the 
fraction of patients who experienced at least one clinically relevant ADRs within the 12-week follow-
up, attributable to the index drug, between the standard of care and the intervention arm. If this is 
statistically significant, a second analysis will be performed, including all patients in the study. This 
second analysis will compare the fraction of patients who experienced at least one clinically relevant 
ADR within the 12-week follow-up,  attributable to the index drug,, between the standard of care 
and the intervention arm. All sites will act as their own controls. The first analysis will quantify the 
absolute impact of PGx based prescribing on the frequency of clinically relevant ADRs, the second 
will quantify the impact of PGx intervention when it is implemented population-wide.  
Secondary Outcomes 
Drug efficacy is not an outcome measure in the PREPARE study. It is not anticipated that PGx guided 
prescribing will have a negative impact on drug efficacy. To provide evidence for this statement, two 
proxy-measures of efficacy will be collected. Firstly, the frequency of drug discontinuation due to 
lack of efficacy will be compared in the standard of care arm to the intervention arm. Secondly, 
routine index drug levels of patients who received a dose alteration as a result of an actionable 
drug/gene combination will be compared to the routine index drug levels of patients who did not 
receive a dose alteration. It is hypothesized that the drug exposures are similar in both arms, and 
that efficacy must therefore also be similar. Data on costs associated with ADRs will be collected to 
perform a country-specific cost-effectiveness analyses. Adherence to PGx guidelines will also be 
collected following every index drug and subsequent drug prescription within the PREPARE study. 
This will yield data on DPWG guideline adherence by both the health care professionals who recruit 
to the PREPARE study and the health care professionals outside the scope of the PREPARE study but 
who manage an episode of routine care for a participant during the study follow up period. The 
research team will contact health care professionals after they have received their patient’s PGx 
results to ask whether or not they complied with the DPWG recommendation. When health care 
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professionals do not comply with the recommendation, they are asked to report reasons for not 
doing so. Patient knowledge of and attitudes towards PGx will also collected at baseline and at the 
end of the study. 
A Step into the Future 
PGx is still an evolving discipline and will undoubtedly be further developed over the years to 
increase the applicability and subsequent impact of PGx on patient outcomes. Our incomplete 
understanding of the genetic impact on drug responses limits the benefits of PGx in clinical care; 
possibly up to 50% of ADRs may be predicted by common genetic determinants. Rare variants may 
also be associated with drug responses or ADRs; using NGS (76-79) and systems pharmacology 
approaches, we may be able to increase our understanding of the role of PGx and thereby 
potentially increase its benefits and impact. The U-PGx consortium will achieve this by using two 
approaches: 1) NGS techniques to identify rare variants that are associated with drug response in 
the extreme phenotype sub-study and 2) through a systems pharmacology approach, non-genetic 
determinants of drug response (such as gender, age, drug-drug interaction) will be integrated to 
create novel, powerful and practice-oriented models of personalized medicine in pharmacokinetic 
sub-studies. Inclusion and exclusion criteria for the sub-studies are listed in Supplemental Table S4.  
Extreme Phenotype Sub-Study 
Patients included in the PREPARE study who either 1) experience a serious ADR which is not 
expected on the basis of the pre-emptive PGx testing results in the PGx intervention arm, or 2) 
experience a serious ADR (already known to be associated with the drug in the DPWG guidelines) 
even though the patient has received an altered drug or dose selection as a result of an actionable 
genotype or 3) experience a serious ADR in the PGx control arm. These “extreme phenotype” 
patients will be flagged and contacted by the research nurse to obtain a blood sample, for drug level 
monitoring, at the time of the ADR for NGS sequencing and detection of plasma levels of the drug if 
interest including relevant metabolites. NGS sequencing will be performed to search for novel 
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variants associated with the extreme phenotype. To identify a possible genetic origin of the extreme 
phenotype, all patients included in the study will be asked to provide informed consent for NGS. This 
data will only be used anonymously for exploratory analysis and not be implemented in clinical care 
or returned to the patient, thereby no potential secondary genetic findings will be returned to the 
patients. Plasma samples of drugs of interest will be detected by previously established methods 
(e.g. HPLC, LC-MS/MS) to perform additionally phenotype (plasma level)-genotype correlation 
analysis.  
Pharmacokinetic Sub-Study 
Patients included in the study after a first prescription of voriconazole, metoprolol, simvastatin, 
atorvastatin, fluorouracil or capecitabine will be asked to provide additional blood samples (see 
Supplemental Table S5) to quantify levels of the parent drug and respective metabolites . Through a 
systems pharmacology approach, non-genetic determinants of drug response (such as gender, age, 
disease related factors, drug-drug interaction) will be integrated to create novel, powerful and 
practice-oriented models of personalized medicine. This work will strive toward assessing the 
relative contribution of PGx to variability in drug response by utilizing pharmacometric models that 
integrate PGx with other sources of variability. The models will describe the events from dose to 
drug response, thus including effects of PGx on pharmacokinetics and pharmacodynamics. 
Physiologically based pharmacokinetic models and(or population pharmacokinetic models will be 
utilised. Clinical endpoint data as well as clinically relevant drug-drug interactions will be extracted 
from PREPARE to be used for adjustment and qualification of model-based analyses.  
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CONCLUSIONS 
In conclusion, the U-PGx Consortium will implement pre-emptive PGx testing involving a panel of 
pharmacogenes into routine care to guide drug and dose selection for 43 drugs, through a multi-
center, block-randomized controlled study. PREPARE aims to assess the impact of implementation 
on ADR incidence and healthcare costs. In parallel, innovative approaches such as pharmacometric 
modelling, NGS and systems pharmacology will be used to expand our understanding of PGx and 
thereby increase its potential benefits and impact.  
We hypothesize successful PGx implementation could drastically decrease the incidence of ADRs and 
could increase the benefit: risk profile of pharmacotherapy. Currently, unacceptable levels of ADRs, 
poor adherence and ineffectiveness are associated with pharmacotherapies for many conditions. 
Each year, adverse drug events are responsible for 5% of hospitalizations, but crucially, PGx 
implementation has the potential to alleviate this. The impact of PGx testing will be maximized when 
implemented population-wide. Since actionable PGx variants are ubiquitous and the results of PGx 
testing are life-long, we foresee a future where everyone undergoes PGx testing. Physicians and 
pharmacists can use these results pre-emptively to optimize drug and dose selection throughout a 
patient’s lifetime. This could ultimately decrease (but not abolish) the incidence of ADRs and their 
associated healthcare service and societal burdens.  
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FIGURE LEGENDS 
Figure 1. An overview of the Ubiquitous Pharmacogenomics (U-PGx) Project. Firstly, tools to enable 
the integration of PGx results into the CDSS will be developed, the DPWG guidelines will be 
translated and participating physicians and pharmacists will be educated in understanding and 
applying PGx during prescription and dispensing. Following this, the PREPARE study will evaluate the 
impact of PGx implementation on clinical outcomes, cost effectiveness and implementation process 
metrics. The PREPARE study will provide data collection for innovative projects, which aim to expand 
our understanding of PGx though next-generation sequencing and a systems pharmacology 
approach. In parallel, the final component supports the ethical proceeding of the project and 
spearheads outreaching and educational activities to influential stakeholders. 
Figure 2. The established expert network of the Ubiquitous Pharmacogenomics (U-PGx) Consortium. 
The U-PGx Consortium consists of four components: 1) Enabling Tools, 2) The PREPARE Study, 3) A 
next step into the future, and 4) Dissemination, communication and ELSI (ethical, legal, and societal 
impact). The institutes listed below are members of the corresponding component.   
 
Table 1. An overview of current clinical implementation studies and programmes across the United 
States and Europe. 
 
Figure 3. The front (top) and back (bottom) of the “Safety-Code card”. This is a plastic card, akin to a 
credit card, carrying an individual’s pharmacogenomic information and a QR code which is 
connected to the individual’s personalized dosing recommendations as per the Dutch 
Pharmacogenomics Working Group. 
 
Figure 4. Timeline of the PREPARE study: in the first year all tools enabling pre-emptive PGx  testing 
(IT, genotyping technology, education, translation and sharing of guidelines) will be prepared and 
finalized. In years 2 to 4 the impact of pre-emptive PGx testing will be evaluated in the PREPARE 
study. Sites (countries where the study is performed) are block-randomized to either implement PGx 
guided prescribing or standard of care for an 18-month block. After this 18-month block, the 
opposite strategy will be implemented, with a new set of recruited patients. 4,050 new patients will 
be recruited in each block. Each site will function as its own control. In parallel, data will be collected 
for innovative projects, which aim to expand the understanding of pharmacogenomics though next-
generation sequencing and systems pharmacology approaches.  
 
Table 2. Actionable drug-gene pairs implemented in routine care in the PREPARE Study as per the 
Dutch Pharmacogenomics Working Group guidelines. 
 
Figure 5. Study logistics in the PREPARE study. Adult patients receiving a first prescription for one of 
the 42 included drugs will be identified and are eligible for inclusion. At recruitment a DNA sample is 
collected for genotyping of a panel of 50 variants in 13 pharmacogenes. The PGx results of patients 
in the intervention arm only will be used to guide drug and dose selection as per the DPWG 
guidelines. Patients in the intervention arm will receive a “Safety-Code card” containing their 
personal PGx results, which can be used by other physicians or pharmacists to guide subsequent 
prescriptions. Patients in the standard of care arm will receive a mock “Safety-Code card”, not 
containing any PGx results but listing the U-PGx eligible drugs. There are two consecutive 18-month 
blocks for recruitment of participants. In one block, participants will receive standard of care; in the 
other block, other participants will receive the PGx intervention. The order of these blocks is 
randomized at each study site. Following recruitment, all patients will be followed-up for three 
months, both by the research nurse (at baseline, 4 weeks and 12 weeks after initiating the index 
drug) and by an online patient reported outcomes survey (at two weeks and eight weeks). In 
addition, a final cross-sectional survey will be performed by the research nurse, at the end of the 
study arm. Follow-up will assess for incident adverse drug events, drug modifications, drug 
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adherence, quality of life, healthcare costs, co-medication and attitudes towards PGx. Assessment of 
adverse drug reactions will be performed by the research team and involves a causality, severity and 
genotype correlation assessment. Patients are requested to report if they newly start any of the 43 
drugs (including oestrogen containing drugs) of interest during follow-up in addition to the index 
drug. This will trigger an identical three month follow-up. 
 
Figure 6. The primary endpoint is the frequency of clinically relevant adverse drug reactions within 
three months of initiating the index drug. All incident adverse drug events will be assessed regarding 
causality (using the Liverpool Causality Assessment Tool), severity (using the NCI-CTCAE scale), and 
association to genotype (using the DPWG guidelines). Only adverse drug events defined as definitely, 
probably or possibly adverse drug reactions according to the Liverpool causality assessment tool, 
classified as severe (defined as NCI-CTCAE Grade 2,3,4 or 5), and associated with a drug-genotype 
pair contribute to the primary endpoint.  
 
 
